Cargando…
Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients
The current antimicrobial market and old (pre-2000) in vitro antimicrobial susceptibility test interpretative criteria (STIC) are not working properly. Malfunctioning susceptibility breakpoints and antimicrobial markets have serious implications for both patients (ie, from a safety and efficacy pers...
Autores principales: | Ambrose, Paul G, Bhavnani, Sujata M, Andes, David R, Bradley, John S, Flamm, Robert K, Pogue, Jason M, Jones, Ronald N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336562/ https://www.ncbi.nlm.nih.gov/pubmed/32667364 http://dx.doi.org/10.1093/ofid/ofaa084 |
Ejemplares similares
-
1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States
por: Flamm, Robert K, et al.
Publicado: (2019) -
1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates
por: Pfaller, Michael A, et al.
Publicado: (2019) -
1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)
por: Pogue, Jason M, et al.
Publicado: (2019) -
2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data
por: Bhavnani, Sujata M, et al.
Publicado: (2018) -
Time for Precision: A World Without Susceptibility Breakpoints
por: Bader, Justin C, et al.
Publicado: (2018)